As CD44+/CD24−/low is the classic stem cell marker in breast cancer [14, 15], and approximately 99% of MDA-MB-231 cells are CD44+ [16], we focused on the level of CD24 in MDA-MB-231 cells with or without NOP14 overexpression. This evidence concerns the gene CD44 and breast carcinoma.